Role of interleukin-22 in liver diseases.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

27 citing papers in PubMed, 46 citations in OpenAlex.

1. Fungal Polysaccharides as Modulators of Molecular Pathways in Liver Health.Molecules (Basel, Switzerland) · 2025
   Review
2. MK2 Inhibition as a Novel Treatment for Fibrosis in Primary Sclerosing Cholangitis via an IL-22-Dependent Mechanism.Cells · 2025
   Article
3. The reciprocal regulation between autophagy and IL-22: implications for immunity and therapy.Clinical and experimental medicine · 2025
   Review
4. Flavonoids as modulators of gut-liver axis: emerging therapeutic strategies for MAFLD.Frontiers in pharmacology · 2025
   Review
5. Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective.Frontiers in cellular and infection microbiology · 2025
   Review
6. Synthetic Biology-Driven Microbial Therapeutics for Disease Treatment.Journal of microbiology and biotechnology · 2024
   Review
7. The Impact of Liver Steatosis on Interleukin and Growth Factors Kinetics during Chronic Hepatitis C Treatment.Journal of clinical medicine · 2024
   Article
8. Current Therapeutic Options and Potential of Mesenchymal Stem Cell Therapy for Alcoholic Liver Disease.Cells · 2022
   Review
9. Therapeutic Opportunities of IL-22 in Non-Alcoholic Fatty Liver Disease: From Molecular Mechanisms to Clinical Applications.Biomedicines · 2021
   Review
10. The good and the bad about separation anxiety: roles of IL-22 and IL-22BP in liver pathologies.Seminars in immunopathology · 2021
    Review
11. IL-22 Binding Protein (IL-22BP) in the Regulation of IL-22 Biology.Frontiers in immunology · 2021
    Review
12. Microbiota-Dependent Effects of IL-22.Cells · 2020
    Review
13. Secretion of Recombinant Interleukin-22 by Engineered Lactobacillus reuteri Reduces Fatty Liver Disease in a Mouse Model of Diet-Induced Obesity.mSphere · 2020
    Article
14. Genetic algorithms identify individuals with high risk of severe liver disease caused by schistosomes.Human genetics · 2020
    Review
15. Immunodysfunction in Acute-on-Chronic Liver Failure.Visceral medicine · 2018
    Review
16. Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker.Molecular medicine (Cambridge, Mass.) · 2018
    Review
17. Enhanced Regeneration and Hepatoprotective Effects of Interleukin 22 Fusion Protein on a Predamaged Liver Undergoing Partial Hepatectomy.Journal of immunology research · 2018
    Article
18. The Interleukin-20 Cytokine Family in Liver Disease.Frontiers in immunology · 2018
    Review
19. The role of IL-22 in the resolution of sterile and nonsterile inflammation.Clinical & translational immunology · 2018
    Review
20. Gut dysbiosis and impairment of immune system homeostasis in perinatally-exposed mice to Bisphenol A precede obese phenotype development.Scientific reports · 2017
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as